TRENDING :  Market Movers  |  Top 50   AAPL (1.12%)    TSLA (1.2%)    TVIX (-6.95%)    TLRY (-0.17%)    T (1.04%)    SPY (0.62%)    SBUX (0.85%)    RIOT (12.22%)    QQQ (0.75%)    QCOM (1.48%)    PSTG (1.95%)    PAH (0%)    MCD (0.2%)    JPM (-0.45%)    IVC (2.28%)    IMDZ (0.18%)    GS (-0.19%)    GOOS (3.61%)    GOOGL (1.12%)    FDX (-0.99%)    FB (1.16%)    EA (-0.98%)    CBS (1.52%)    BILI (7.39%)    BIDU (-2.71%)

Robert Gadimian

Joined: 8/5/2017
Education: Graduate
Trading Experience: 10-20 yrs
I have 20 years of experience in trading. I also have a extensive experience with drug development. I combine technical analysis, valuation of the company and the upcoming short term catalysts before trading. I will set a target price and very tight stop loss limits. I am an active trader and usually sell and jump in again in the same stock until it hits the target price. I like to take my profit after the little runs that the stocks have. It is a more conservative and profitable approach.


Learn More...

132

Total Recommendations

-2

Open Recommendations

26.12 %

Success Rate

1

Total Services

My Services

Service NameAvg % Return
since Inception
Recommendations
Open/Closed
% SuccessYTD ReturnRiskFees
Biotechnology-1.01 %-2/13426.12 %0.00 %
-4.95
FreeFollow

Closed Recommendations

SymbolServiceTypeStrategy Created Closed% Return
AIMTBiotechnologyEquityBuy Long03/23/1804/03/18-5.04 %
IDRABiotechnologyEquityBuy Long01/26/1804/02/18-9.57 %
ADMSBiotechnologyEquityBuy Long03/23/1804/02/18-6.31 %
AVDLBiotechnologyEquityBuy Long03/23/1803/27/18-4.26 %
PRTKBiotechnologyEquityBuy Long03/23/1803/27/18-3.70 %
CDTXBiotechnologyEquityBuy Long03/23/1803/26/18-9.09 %
CPRXBiotechnologyEquityBuy Long03/23/1803/23/18-2.26 %
AKAOBiotechnologyEquityBuy Long01/02/1803/23/1819.40 %
ADXSBiotechnologyEquityBuy Long03/05/1803/12/1810.61 %
SGYPBiotechnologyEquityBuy Long12/13/1703/05/1811.11 %
LXRXBiotechnologyEquityBuy Long12/21/1702/09/18-13.29 %
NLNKBiotechnologyEquityBuy Long01/12/1802/06/18-6.54 %
PRTKBiotechnologyEquityBuy Long01/26/1802/02/18-4.15 %
TTPHBiotechnologyEquityBuy Long01/11/1802/01/18-15.38 %
QTNTBiotechnologyEquityBuy Long01/26/1801/31/18-8.26 %
ADMPBiotechnologyEquityBuy Long12/21/1701/29/18-14.61 %
ACRXBiotechnologyEquityBuy Long12/13/1701/26/180.00 %
RNNBiotechnologyEquityBuy Long10/25/1701/26/1822.53 %
SCYXBiotechnologyEquityBuy Long01/12/1801/16/18-2.63 %
KDMNBiotechnologyEquityBuy Long12/13/1701/12/188.38 %
TLGTBiotechnologyEquityBuy Long01/11/1801/12/18-4.95 %
TGTXBiotechnologyEquityBuy Long12/07/1701/11/1825.45 %
ARDMBiotechnologyEquityBuy Long01/04/1801/09/18-21.88 %
OVASBiotechnologyEquityBuy Long12/22/1701/04/18-7.59 %
EYEGBiotechnologyEquityBuy Long12/13/1701/03/18-9.92 %
ICPTBiotechnologyEquityBuy Long12/22/1701/02/18-7.58 %
AKTXBiotechnologyEquityBuy Long10/25/1712/22/174.05 %
RXIIBiotechnologyEquityBuy Long11/30/1712/21/17-15.91 %
KALABiotechnologyEquityBuy Long11/10/1712/13/17-7.81 %
EVOKBiotechnologyEquityBuy Long11/14/1712/13/17-10.39 %
ACRXBiotechnologyEquityBuy Long12/07/1712/12/17-9.09 %
LXRXBiotechnologyEquityBuy Long11/30/1712/12/17-4.11 %
OVASBiotechnologyEquityBuy Long11/30/1712/12/17-9.40 %
SGYPBiotechnologyEquityBuy Long11/15/1712/07/17-3.19 %
KDMNBiotechnologyEquityBuy Long11/03/1712/07/17-4.23 %
CNATBiotechnologyEquityBuy Long11/30/1712/06/17-6.92 %
ARLZBiotechnologyEquityBuy Long11/21/1711/30/17-3.27 %
ICPTBiotechnologyEquityBuy Long11/21/1711/28/17-3.77 %
TSROBiotechnologyEquityBuy Long11/15/1711/28/17-7.85 %
ZIOPBiotechnologyEquityBuy Long11/14/1711/21/170.71 %
PTCTBiotechnologyOptionsBuy Puts10/12/1711/17/17-96.43 %
PTCTBiotechnologyOptionsBuy Puts10/02/1711/17/17-96.15 %
ADMPBiotechnologyEquityBuy Long10/18/1711/15/17-10.00 %
ARDXBiotechnologyEquityBuy Long11/03/1711/14/17-8.62 %
TSROBiotechnologyEquityBuy Long11/14/1711/14/17-1.54 %
IOVABiotechnologyEquityBuy Long10/25/1711/14/179.79 %
RDHLBiotechnologyEquityBuy Long11/10/1711/14/17-4.49 %
TCONBiotechnologyEquityBuy Long11/03/1711/13/17-6.78 %
AKAOBiotechnologyEquityBuy Long11/08/1711/13/17-3.97 %
KERXBiotechnologyEquityBuy Long11/08/1711/10/17-4.59 %
ZIOPBiotechnologyEquityBuy Long11/08/1711/10/17-5.06 %
ATNMBiotechnologyEquityBuy Long10/11/1711/08/17-16.38 %
ICPTBiotechnologyEquityBuy Long09/29/1711/08/178.26 %
NVTABiotechnologyEquityBuy Long11/03/1711/07/17-3.73 %
TGTXBiotechnologyEquityBuy Long10/19/1711/03/173.90 %
MNOVBiotechnologyEquityBuy Long10/10/1710/27/177.61 %
KERXBiotechnologyEquityBuy Long10/26/1710/27/17-3.00 %
ARDXBiotechnologyEquityBuy Long10/18/1710/26/17-11.50 %
TSROBiotechnologyEquityBuy Long10/25/1710/26/17-0.35 %
AKAOBiotechnologyEquityBuy Long10/11/1710/25/17-4.90 %
TSROBiotechnologyEquityBuy Long10/19/1710/25/17-3.66 %
RNNBiotechnologyEquityBuy Long10/13/1710/25/17-13.88 %
LXRXBiotechnologyEquityBuy Long10/17/1710/24/17-4.34 %
ACRSBiotechnologyEquityBuy Long10/17/1710/23/17-1.75 %
TGTXBiotechnologyEquityBuy Long10/18/1710/18/17-3.66 %
SGYPBiotechnologyEquityBuy Long10/17/1710/18/17-5.19 %
TSROBiotechnologyEquityBuy Long10/12/1710/18/17-1.21 %
TCONBiotechnologyEquityBuy Long10/03/1710/17/17-13.04 %
QTNTBiotechnologyEquityBuy Long10/02/1710/17/17-6.86 %
ALDXBiotechnologyEquityBuy Long10/04/1710/16/17-7.38 %
ANTHBiotechnologyEquityBuy Long10/12/1710/16/17-6.98 %
IMDZBiotechnologyEquityBuy Long10/12/1710/16/17-2.73 %
AXSMBiotechnologyEquityBuy Long10/02/1710/13/17-7.08 %
ARDXBiotechnologyEquityBuy Long09/19/1710/12/1738.39 %
GBTBiotechnologyEquityBuy Long10/04/1710/12/175.65 %
ACRXBiotechnologyEquityBuy Long08/05/1710/12/17-13.79 %
AERIBiotechnologyEquityBuy Long10/02/1710/11/1720.97 %
TRVNBiotechnologyEquityBuy Long10/02/1710/10/17-6.84 %
AXONBiotechnologyEquityBuy Long10/03/1710/10/17-11.10 %
MTFBBiotechnologyEquityBuy Long09/19/1710/04/1733.49 %
HRTXBiotechnologyEquityBuy Long09/13/1710/03/1714.24 %
FLXNBiotechnologyEquityBuy Long09/29/1710/03/179.74 %
NUVABiotechnologyEquityBuy Long09/25/1710/02/170.11 %
ANTHBiotechnologyEquityBuy Long09/29/1709/29/17-4.11 %
ZGNXBiotechnologyEquityBuy Long09/05/1709/29/17134.40 %
RDHLBiotechnologyEquityBuy Long09/11/1709/28/1721.36 %
CATBBiotechnologyEquityBuy Long09/08/1709/28/1737.93 %
ICPTBiotechnologyEquityBuy Long09/26/1709/27/17-2.03 %
ICPTBiotechnologyEquityBuy Long09/22/1709/26/17-8.90 %
FLXNBiotechnologyEquityBuy Long09/08/1709/25/177.63 %
TRVNBiotechnologyEquityBuy Long09/20/1709/22/17-2.81 %
NBRVBiotechnologyEquityBuy Long09/20/1709/22/17-2.28 %
VSARBiotechnologyEquityBuy Long09/14/1709/20/1721.88 %
IDRABiotechnologyEquityBuy Long09/05/1709/19/1722.58 %
ACRSBiotechnologyEquityBuy Long09/11/1709/18/17-4.92 %
RXDXBiotechnologyEquityBuy Long09/13/1709/18/1715.38 %
NBRVBiotechnologyEquityBuy Long09/13/1709/15/17-7.06 %
VSARBiotechnologyEquityBuy Long09/13/1709/14/17-4.76 %
TGTXBiotechnologyEquityBuy Long09/07/1709/12/17-4.88 %
VSARBiotechnologyEquityBuy Long09/08/1709/12/17-5.18 %
HZNPBiotechnologyEquityBuy Long08/14/1709/11/1713.91 %
ADMPBiotechnologyEquityBuy Long09/08/1709/11/17-2.75 %
RDHLBiotechnologyEquityBuy Long09/08/1709/11/17-3.42 %
PETXBiotechnologyEquityBuy Long08/30/1709/08/1711.54 %
AUPHBiotechnologyEquityBuy Long09/06/1709/08/178.99 %
PCRXBiotechnologyEquityBuy Long08/30/1709/07/170.41 %
AXSMBiotechnologyEquityBuy Long08/30/1709/07/17-9.00 %
AXSMBiotechnologyEquityBuy Long08/30/1709/07/17-9.00 %
AXSMBiotechnologyEquityBuy Long08/30/1709/07/17-9.00 %
NVTABiotechnologyEquityBuy Long08/28/1709/06/17-2.44 %
AUPHBiotechnologyEquityBuy Long09/01/1709/05/17-2.48 %
LXRXBiotechnologyEquityBuy Long08/31/1709/05/17-2.32 %
FGENBiotechnologyEquityBuy Long08/23/1708/31/1713.99 %
INSMBiotechnologyEquityBuy Long08/17/1708/30/172.73 %
INSMBiotechnologyEquityBuy Long08/24/1708/30/17-2.28 %
PGNXBiotechnologyEquityBuy Long08/10/1708/30/1722.80 %
KMDABiotechnologyEquityBuy Long08/16/1708/30/172.41 %
NVTABiotechnologyEquityBuy Long08/22/1708/24/176.05 %
PCRXBiotechnologyEquityBuy Long08/22/1708/23/17-3.45 %
PCRXBiotechnologyEquityBuy Long08/14/1708/21/17-3.66 %
OMERBiotechnologyEquityBuy Long08/16/1708/21/17-5.60 %
ADMPBiotechnologyEquityBuy Long08/05/1708/17/170.00 %
KMDABiotechnologyEquityBuy Long08/14/1708/15/17-5.49 %
AXSMBiotechnologyEquityBuy Long08/05/1708/14/17-14.05 %
PCRXBiotechnologyEquityBuy Long08/10/1708/11/17-2.59 %
VSTMBiotechnologyEquityBuy Long08/09/1708/10/17-7.04 %
ARLZBiotechnologyEquityBuy Long08/05/1708/10/17-5.17 %
LXRXBiotechnologyEquityBuy Long08/09/1708/10/17-2.88 %
SRPTBiotechnologyEquityBuy Long08/05/1708/10/17-3.34 %
ABIOBiotechnologyEquityBuy Long08/09/1708/10/17-11.11 %
PGNXBiotechnologyEquityBuy Long08/05/1708/09/17-7.09 %
ADMPBiotechnologyEquityBuy Long08/07/1708/09/17-5.32 %
ABIOBiotechnologyEquityBuy Long08/05/1708/09/17-12.82 %
LXRXBiotechnologyEquityBuy Long08/05/1708/07/17-2.72 %

TRENDING ARTICLES




ASIA ECONOMICS: China Shares Rally as Trade Talks Continue

02/22/19
The Shanghai Composite index climbed 52 points or 1 9 to 2 804 Friday ahead of the conclusion of U S China trade talks in Washington with media reports suggesting that Chinese Vice Premier Liu He will meet U S President Trump later in the day said Trading Economics Gains came in

Warren Buffett and the Insurance Business: A 52-Year Love Story

02/22/19
On Feb 22 2019 it will be 52 years to the day since Warren Buffett took his first serious dive into the insurance business when Berkshire Hathaway NYSE BRK A NYSE BRK B entered into an agreement to acquire National Indemnity Company and another smaller insurer for 8

39 Million Americans Have Been in Debt for at Least 2 Years -- and This Is a Big Reason Why

02/22/19
Americans are notorious for racking up credit card debt but new data from CreditCards com reveals a frightening statistic A good 39 million Americans have been carrying credit card debt for at least two years Meanwhile 14 of folks with credit card debt have been carrying a

Reliance Steel (RS) Earnings Lag, Sales Beat Estimates in Q4

02/22/19
Reliance Steel amp Aluminum Co RS 160 posted profit of 85 6 million or 1 22 per share in the fourth quarter of 2018 down roughly 72 from 301 4 million or 4 09 in the year ago quarter The bottom line in the reported quarter was hurt by a hefty LIFO inventory expense

Donald Trump Was Done Paying Social Security Tax Before 2 a.m. on January 1

02/22/19
No one enjoys paying taxes but the American public also understands that paying tax is what helps fund federal state and local government as well as supports local and broad based social programs arguably none of which is more important than Social Security Despite

Why Arista Networks Has More Upside Ahead in 2019

02/22/19
Though 2018 ended on a sour note shares of cloud computing hardware provider Arista Networks NYSE ANET have been rallying on strong results It has become a leader in data center and related technology including 100G and the new 400G speed standards and the hardware

Walmart, Not Amazon, Was the Retail Disruptor in 2018

02/22/19
Walmart Inc NYSE WMT had a monster 2018 holiday shopping season Though many news outlets fretted over disappointing retail sales results there was no such problem for the king of retail Comparable sales which combines foot traffic and average customer ticket size in the U

Air Lease (AL) Q4 Earnings Top on Fleet Growth, Revenues Lag

02/22/19
Air Lease Corporation AL delivered better than expected earnings but lower than expected revenues in the fourth quarter of 2018 The company s earnings excluding 41 cents from non recurring items of 1 65 per share surpassed the Zacks Consensus Estimate of 1 35 The bottom line

How Much Damage Can 1 Bad Experience Cause a Brand?

02/22/19
Consumers have more choices about nearly every purchase than they ve ever had before It s no longer necessary to visit a physical store to buy most things and for the vast majority of products shoppers can pick from multiple retailers on their phone or computer In some measure

Validea Peter Lynch Strategy Daily Upgrade Report - 2/22/2019

02/22/19
The following are today s upgrades for Validea s P E Growth Investor model based on the published strategy of Peter Lynch This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets The following are today s upgrades

Validea Martin Zweig Strategy Daily Upgrade Report - 2/22/2019

02/22/19
The following are today s upgrades for Validea s Growth Investor model based on the published strategy of Martin Zweig This strategy looks for growth stocks with persistent accelerating earnings and sales growth reasonable valuations and low debt The following are today s upgrades

Validea Kenneth Fisher Strategy Daily Upgrade Report - 2/22/2019

02/22/19
The following are today s upgrades for Validea s Price Sales Investor model based on the published strategy of Kenneth Fisher This value strategy rewards stocks with low P S ratios long term profit growth strong free cash flow and consistent profit margins The following are today s

Validea Joseph Piotroski Strategy Daily Upgrade Report - 2/22/2019

02/22/19
The following are today s upgrades for Validea s Book Market Investor model based on the published strategy of Joseph Piotroski This value quant strategy screens for high book to market stocks and then separates out financially sound firms by looking at a host of improving

Validea John Neff Strategy Daily Upgrade Report - 2/22/2019

02/22/19
The following are today s upgrades for Validea s Low PE Investor model based on the published strategy of John Neff This strategy looks for firms with persisten t earnings growth that trade at a discount relative to their earnings growth and dividend yield The following are today s

Validea Joel Greenblatt Strategy Daily Upgrade Report - 2/22/2019

02/22/19
The following are today s upgrades for Validea s Earnings Yield Investor model based on the published strategy of Joel Greenblatt This value model looks for companies with high return on capital and earnings yields The following are today s upgrades for Validea sEarnings Yield Investor
  
© StockHoot LLC 2019. Made in Chicago.

Terms  | Privacy Policy  | Contact Us  | Feedback 






We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.

Cryptocurrency data provided by CryptoCompare